Five financial analysts have recently updated their ratings on G1 Therapeutics (NASDAQ:GTHX), showing a predominantly bullish outlook with four bullish and one somewhat bullish ratings. The 12-month price targets suggest an average of $10.4, with a high of $12.00 and a low of $4.00, indicating a 9.47% increase from the previous average target of $9.50. Analyst actions include maintaining and lowering ratings, reflecting responses to market dynamics and company performance. G1 Therapeutics, a biopharmaceutical company focused on cancer treatment, has shown a revenue growth of 45.1% but faces challenges in debt management and efficiency in using equity capital.